2012•Zhongguo yiyuan yongyao pingjia yu fenxiRequires access

Efficacy of Moxifloxacin vs. Azithromycin Plus Cefoperazone/Sulbactam for Community Acquired Pneumonia

Guan Bing-en

Abstract

OBJECTIVE: To evaluate the clinical efficacy and safety of moxifloxacin versus azithromycin(of similar antimicrobial spectrum) plus cefoperazone/sulbactam in the treatment of community acquired pneumonia.METHODS: 66 patients with community acquired pneumonia were randomized divided into 2 groups,of 33 each.The trial group received moxifloxacin(0.4 g,q.d) by iv gtt and the control group received azithromycin(0.5 g,q.d) plus cefoperazone/sulbactam(2.5 g,bid) by iv gtt.RESULTS: After treatment completion,there were no statistical differences between the two groups in respect of therapeutic effect,bacterium clearance rate and adverse drug reactions(P0.05).CONCLUSION: Moxifloxacin is proved to be effective and as safe as azithromycin plus cefoperazone/sulbactam in the treatment of community acquired pneumonia.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Azithromycin, Moxifloxacin, Cefoperazone, Medicine, Community-acquired pneumonia, Sulbactam, Pneumonia, Internal medicine